Will taking dasatinib reduce white blood cells?

Dasatinib (Dasatinib) is a kinase inhibitor used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) . Ph+CML is a type of leukemia or blood cancer. When patients have Ph+ CML, an abnormal protein called BCR-ABL causes the bone marrow to produce too many immature or damaged white blood cells. These damaged white blood cells cannot work properly and crowd out normal white blood cells, red blood cells, and platelets.

Dasatinib may help inhibitBCR ABL. Dasatinib works by helping to reduce the number of damaged white blood cells in the body. This decrease may result in the production of more normal blood cells. Dasatinib blocks the proliferation and survival of leukemia cells by inhibiting abnormally active tyrosine kinases, thereby reducing the symptoms of leukemia and helping to control the progression of the disease. Be aware that dasatinib may cause a low red blood cell count (anemia), a low white blood cell count (neutropenia), and a low platelet count (thrombocytopenia).

During treatment, doctors typically monitor patients' blood cell counts regularly to ensure dasatinib is effective and safe. If the number of white blood cells drops too much or reaches a certain threshold, your doctor may take appropriate measures, such as adjusting the dose, pausing treatment, or using other medications to help restore normal blood cell levels.

In addition, in order to reduce the side effects caused by the drug Dasatinib (Dasatinib), patients can also pay attention to some self-care measures, such as a good diet, avoiding contact with sources of infection, and regular exercise. It is also important to work closely with your doctor and medical team to promptly report any discomfort or changes.